Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
-5.4%
$0.23
$0.14
$0.63
$10.13M1.626.81 million shs1.05 million shs
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
$3.01
+19.0%
$1.55
$0.81
$3.20
$101.85M-0.27140,959 shs262,698 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.96
-2.0%
$2.40
$1.86
$8.40
$58.34M-0.38152,219 shs322,674 shs
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
$11.00
$11.00
$0.00
$12.48
$62.26M-0.112 shs99 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%-16.41%-34.36%-37.05%-36.88%
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
+8.58%+36.02%+76.92%+67.68%+91.68%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
+1.52%-0.50%-27.27%-56.33%-63.70%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00%0.00%0.00%0.00%+10.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
1.5368 of 5 stars
0.03.00.04.62.51.70.0
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
2.1904 of 5 stars
3.53.00.00.02.01.70.0
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
2.0534 of 5 stars
3.80.00.00.02.60.00.6
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
2.50
Moderate BuyN/AN/A
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00132.56% Upside
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
3.50
Strong Buy$15.00665.31% Upside
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GLYC, OKYO, TELO, and VHAQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2025
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/21/2025
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,013.15N/AN/A$0.08 per share1.96
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.20) per shareN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
-$16.83MN/A0.00N/AN/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%8/12/2025 (Estimated)
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
-$610KN/A0.00N/AN/AN/AN/AN/A

Latest GLYC, OKYO, TELO, and VHAQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$0.05-$0.04+$0.01-$0.04N/AN/A
5/12/2025Q1 2025
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
N/A
0.28
N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
1.94
1.94
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
2.97%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
22.14%

Insider Ownership

CompanyInsider Ownership
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
8.70%
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
40.46%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
75.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionOptionable
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
733.84 million20.15 millionNot Optionable
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
129.76 millionN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
25.66 million1.40 millionNot Optionable

Recent News About These Companies

Viveon Health Acquisition Corp
Clearday, Inc. (CLRD)
VHAQ-R Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. (VHAQ-RT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-5.42%)
Closing price 04:00 PM Eastern
Extended Trading
$0.16 0.00 (-1.27%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$3.01 +0.48 (+18.97%)
Closing price 04:00 PM Eastern
Extended Trading
$3.20 +0.19 (+6.15%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Telomir Pharmaceuticals stock logo

Telomir Pharmaceuticals NASDAQ:TELO

$1.96 -0.04 (-2.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 0.00 (-0.20%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Viveon Health Acquisition stock logo

Viveon Health Acquisition NYSE:VHAQ

$11.00 0.00 (0.00%)
As of 01/30/2025

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.